What is Recipharm?
Established in 1995, Recipharm operates as a vital link in the pharmaceutical supply chain, providing comprehensive development and manufacturing services. The company specializes in managing the lifecycle of pharmaceutical products, offering expertise that spans formulation development, clinical trial supply, and large-scale commercial manufacturing. Its market position is defined by its ability to provide high-quality, regulatory-compliant solutions that allow pharmaceutical innovators to focus on research while Recipharm handles the technical complexities of production.
The organization's operational model is built on a foundation of technical excellence and strategic acquisitions, enabling it to serve a diverse global client base. By maintaining state-of-the-art facilities and adhering to stringent quality standards, Recipharm has become an essential entity for firms seeking to optimize their manufacturing processes and accelerate time-to-market for critical therapies.
How much funding has Recipharm raised?
Recipharm has raised a total of $612.4M across 8 funding rounds:
Share Placement
$20M
Debt
$101.3M
Stock Offering
$87M
Debt
$160.2M
Stock Offering
$29.5M
Debt
$106.8M
Stock Offering
$54.2M
Stock Offering
$53.4M
Share Placement (2011): $20M with participation from Nordea Funds
Debt (2012): $101.3M led by Swedbank AB
Stock Issuance/Offering (2014): $87M supported by Undisclosed
Debt (2014): $160.2M featuring Handelsbanken, DNB, and Swedbank
Stock Issuance/Offering (2016): $29.5M backed by Undisclosed
Debt (2016): $106.8M with participation from Undisclosed
Stock Issuance/Offering (2018): $54.2M led by Undisclosed
Stock Issuance/Offering (2020): $53.4M supported by Polar Capital, Gladiator, and Lansforsakringar
Key Investors in Recipharm
Polar Capital
A specialized investment management firm focused on active management across a range of equity and alternative strategies.
Gladiator
An investment entity known for its participation in strategic growth rounds and long-term capital support for established enterprises.
Lansforsakringar
A major Swedish financial group providing banking and insurance services, often acting as a key institutional investor in regional industrial growth.
What's next for Recipharm?
Looking ahead, the strategic deployment of $53.4M is expected to catalyze further operational efficiencies and potential expansion into emerging therapeutic modalities. As the pharmaceutical industry faces increasing pressure to innovate rapidly, Recipharm is well-positioned to utilize its financial backing to invest in advanced manufacturing technologies and capacity upgrades. This proactive approach to capital management ensures that the company remains at the forefront of the CDMO landscape, capable of meeting the evolving demands of global healthcare providers and drug developers alike.
The firm's focus will likely remain on strengthening its core competencies while exploring opportunities to integrate digital manufacturing solutions and sustainable production practices. By maintaining a disciplined approach to growth and leveraging its established market presence, Recipharm is poised to continue its role as a cornerstone of the pharmaceutical manufacturing ecosystem.
